Connect Biopharma seen posting 27-cent loss per share on revenue jump
Seven analysts polled by LSEG expect Connect Biopharma to post a 27-cent loss per share and $771.43 thousand in revenue, according to Earnings Preview.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Earnings Preview reports that Connect Biopharma Holdings, a San Diego-based company, is due to publish quarterly figures around November 10, covering the period through September 30, 2026. Seven analysts polled by LSEG forecast revenue of $771.43 thousand, up 34,338.8% from $2.24 thousand a year earlier, and a loss of 27 cents per share.
The consensus rating is buy, with no hold or sell recommendations, and the mean earnings estimate has not changed over the past three months. The median 12-month price target stands at $6.00, compared with a last close of $0.73.
why it matters
The percentage gain looks dramatic mainly because the base is very small, with revenue of just $2.24 thousand a year ago. The company's recent record is mixed: the June quarter loss of 27 cents beat the LSEG estimate of 31 cents, while the March quarter came in well below expectations. Investors will likely watch whether the reported numbers match the analysts' forecasts.
tags
instruments
sources
- Connect Biopharma Holdings Ltd expected to post a loss of 27 cents a share — Earnings Preview, 6 November 2026 at 23:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗